Targeted protein degradation · Antibody conjugation · Oncology therapeutics
Orum Therapeutics
A biotech combining targeted-protein-degradation with antibodies, out-licensing next-generation cancer candidates to global pharma. KOSDAQ large-cap constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
475830.KQ Updated Jul 11, 2026 2 AI consumers· 1 recurring
Annual return · 2026-09-04YTD-50.5%
Money in ▸·
Orum Therapeutics
▸ Money out·
Financials & Segments
- Segments · Drug development (TPD/antibody) · Licensing-out
Revenue from
No refined links yet.
Pays to
No refined links yet.